American Society of Hematology

2017 Special-Interest Sessions

These smaller sessions provide the opportunity for ASH’s various communities to focus on specific topics of interest, ranging from coping with physician stress and burnout, to counseling fellows on careers in hematology, to the impact of ASH’s international outreach programs.

AML MATTERS: A Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection

Saturday, December 9, 2017, 4:00 p.m. - 5:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 3- Georgia BR 1-3

AML Matters is an education program designed to improve the diagnosis and treatment of acute myeloid leukemia (AML). The program is being hosted by the American Society of Hematology, American Society for Clinical Pathology, National Marrow Donor Program, Oncology Nursing Society, and The France Foundation.

AML was diagnosed in approximately 20,000 people in the United States in 2016, and of those patients over half will die from this disease. Recently, there have been significant advances in the diagnosis and management of AML, which warrant ongoing education for the interdisciplinary care team involved in the management of patients with AML.

This educational program will provide guidance to the interdisciplinary AML care team on the optimal diagnosis and classification of AML, risk stratification, and individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and patient education regarding prognosis and treatment choices.

The target audience for this initiative includes hematology/oncology physicians, advance practice professionals, and nurses; hematopathologists/pathologists; HCT clinicians, and other healthcare professionals.

Chair:

Jessica K. Altman, MD
Northwestern University Feinberg School of Medicine
Chicago, IL

Speakers:

Robert P. Hasserjian, MD
Massachusetts General Hospital
Boston, MA
What is Therapy-Related Myeloid Neoplasm (t-MN)? A Look at History, Morphology, Cytogenetics, and Molecular Studies

Jessica K. Altman, MD
Northwestern University Feinberg School of Medicine
Chicago, IL
Has Our Approach to Treatment Changed in the Era of Recently Approved Therapies?

Linda J. Burns, MD
National Marrow Donor Program/Be the Match
Minneapolis, MN
How Do We Approach Transplant in the Era of Targeted Therapies?

Kathleen Wiley, RN, MSN, AOCNS
Oncology Nursing Society
Pittsburgh, PA
What Tools Can We Use to Counsel Our Patients in the Setting of Novel Therapies?

back to top

ASH Choosing Wisely® Campaign: 2017 ASH Choosing Wisely Champions

Monday, December 11, 2017, 12:15 p.m. - 1:15 p.m.
Georgia World Congress Center, Bldg C- Lvl 2- C202-C204

In cooperation with the ABIM Foundation, ASH has introduced the Choosing Wisely Champions initiative to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures. Each year, three individuals are invited to present on successful utilization strategies that they have developed and implemented in their practice, institution, or hospital system, providing clinicians, administrators, and other medical professionals with opportunities to learn about projects that might be translated to their own practices.

Chair:

Lisa K. Hicks, MD, MSc
St. Michael's Hospital
Toronto, ON, Canada

Speakers:

Matthew R. Schefft, DO, MSHA
Virginia Commonwealth University
Richmond, VA
Reduction in admission rate for children with SCD presenting with vaso-occlusive crisis (VOC) via initiation of individualized pain plans (IPPs)

Yulia Lin, MD
Sunnybrook Health Sciences Center
Toronto, ON, Canada
Reduction of inappropriate transfusions for patients with iron deficiency anemia (IDA) in the Emergency Department (ED) via guidelines and physician education

Marc Stuart Zumberg, MD
University of Florida
Gainesville, FL
Improvement of compliance and utilization of recombinant VIIa, prothrombin complex concentrates (PCCs), and blood products

back to top

ASH Foundation Run/Walk

Sunday, December 10, 2017, 7:30 a.m. - 9:00 a.m.
International Plaza

Start your day in a fun, healthy, and philanthropic way by participating in the fifth annual ASH Foundation Run/Walk before attending the Sunday sessions. Participants may run or walk through the designated event course in Atlanta, choosing either a 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Sickle Cell Disease Initiative Fund. ASH and the ASH Foundation may opt to designate a portion or all of corporate sponsorship revenues associated with the Run/Walk to help support the cost of administering the event.

Learn more and register at www.hematology.org/runwalk. back to top

ASH Grassroots Network Lunch

Saturday, December 9, 2017, 11:15 a.m. - 12:15 p.m.
Omni Hotel at CNN Center, Int'l Blrm- No. Twr- M2

Thanks to ASH’s advocacy efforts and the ASH Grassroots Network, issues important to the future of hematology have been brought to the attention of the U.S. Congress and federal agencies.  The ASH Grassroots Lunch provides a forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress and the White House, become effective advocates for hematology, and discuss the Society’s legislative and regulatory priorities, including funding for the National Institutes of Health (NIH).  Alan Wurtzel, a special advisor at NBC Universal and former President of Research and Media Development at NBCUniversal, will be the featured speaker at this year’s lunch.  Mr. Wurtzel will discuss issues impacting the changing political and media landscapes in Washington and share his perspectives on how the media – as well as hematology advocates – have a responsibility to use truth to impact public opinion and policy.

Speaker:

Alan Wurtzel, Special Advisor
NBCUniversal
New York, 

back to top

ASH Practice Partnership Lunch

Physician Stress and Burnout

Sunday, December 10, 2017, 11:15 a.m. - 12:30 p.m.
Omni Hotel at CNN Center, Int'l Blrm- No. Twr- M2

The ASH Practice Partnership is the Society’s network of practice-based hematologists with interests in practice-related policies, quality of care, new health care delivery systems, and practice management issues. The ASH Practice Partnership Lunch is a special session designed for this community.

A December 2015 study from the Mayo Clinic reported that physician burnout is on the rise; across all medical specialties, the physician burnout rate rose from 45 percent in 2011 to 54 percent in 2014. In 2015, ASH Clinical News reported in "Beating Burnout: When Clinicians Are Overworked, Overtired, and Overwhelmed" that the most common complaints among today’s practicing hematologists are delayed, inadequate, and reduced reimbursement, high staff turnover, poor recruitment and retention, and understaffing – all causes of burnout. Reports indicate that the advent of electronic health records and federal reporting mandates have added to physician burnout and that the implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) has the potential to create additional burden, especially for small practices lacking in administrative resources. Speakers will address the problem of physician burnout and focus on sustainability, proposing coping methods and potential solutions.

Moderator:

Kenneth Adler, MD
Summit Medical Group, MD Anderson Cancer Center
Morristown, NJ

Speakers:

Linda J. Burns, MD
National Marrow Donor Program/Be the Match
Minneapolis, MN
Physician Stress and Burnout

Beth Lown, MD
Harvard Medical School, Mount Auburn Hospital
Boston, MA
Physician Stress and Burnout

Tait D. Shanafelt, MD
Mayo Clinic
Rochester, MN
Physician Stress and Burnout

back to top

ASH-FDA Joint Symposium on New Drug Approvals in Acute Lymphoid Leukemia and Non-Hodgkin Lymphoma

Sunday, December 10, 2017, 4:30 p.m. - 6:00 p.m.
Georgia World Congress Center, Bldg C- Lvl 1- Hall C2-C3

This joint session, co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematologic disorders. FDA product-reviewers will discuss the safety and efficacy issues from the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time at the end of the session for audience questions.

Chair:

Richard Pazdur, MD
U.S. Food and Drug Administration
Silver Spring, MD

Speakers:

Angelo De Claro, MD
U.S. Food and Drug Administration
Silver Spring, MD
New Drug Options for Patients: FDA at Work

Emily Y. Jen, MD,PhD
U.S. Food and Drug Administration
Silver Spring, MD
Tisagenlecleucel: The First CAR-T Cell Approval

Tanya Wroblewski, MD
U.S. Food and Drug Administration
Silver Spring, MD
Inotuzumab Ozogamicin: The First Antibody-Drug Conjugate for ALL

Crystal L. Mackall, MD
Stanford University
Stanford, CA
ALL Clinical Perspective

Richard Pazdur, MD
U.S. Food and Drug Administration
Silver Spring, MD
ALL Panel Discussion

Yvette L. Kasamon, MD
U.S. Food and Drug Administration
Silver Spring, MD
Axicabtagene Ciloleucel: A Paradigm Shift for Large B-cell Lymphomas

Nicholas Richardson, DO
U.S. Food and Drug Administration
Silver Spring, MD
Copanlisib: A New PI3K Inhibitor

Margret Merino, MD
U.S. Food and Drug Administration
Silver Spring, MD
Acalabrutinib: On-Target for BTK

Helen E. Heslop, MD,DSc
Baylor College of Medicine
Houston, TX
NHL Clinical Perspective

Richard Pazdur, MD
U.S. Food and Drug Administration
Silver Spring, MD
NHL Panel Discussion

back to top

ASH-FDA Joint Symposium on New Drug Approvals in Acute Myeloid Leukemia

Monday, December 11, 2017, 4:30 p.m. - 6:00 p.m.
Georgia World Congress Center, Bldg C- Lvl 1- Hall C2-C3

This joint session, co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat acute myeloid leukemia (AML). FDA product-reviewers will discuss the safety and efficacy issues from the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time at the end of the session for audience questions.

Chair:

Richard Pazdur, MD
U.S. Food and Drug Administration
Silver Spring, MD

Speakers:

Ashley F. Ward, MD
U.S. Food and Drug Administration
Silver Spring, MD
Defining Clinical Benefit: Evolving Regulatory Considerations for Drug Development in AML

Ashley F. Ward, MD
U.S. Food and Drug Administration
Silver Spring, MD
Midostaurin: Improved Survival, but Does Maintenance Matter?

Aviva C. Krauss, MD
U.S. Food and Drug Administration
Silver Spring, MD
(Daunorubicin and Cytarabine) Liposome Injection: What’s Old is New Again

Laura C. Michaelis, MD
Medical College of Wisconsin
Milwaukee, WI
Clinical Considerations of Using CPX Upfront and of Using Midostaurin Upfront

Kelly J Norsworthy, MD
U.S. Food and Drug Administration
Silver Spring, MD
Gemtuzumab Ozogamicin: Then and Now

Ashley F. Ward, MD
U.S. Food and Drug Administration
Silver Spring, MD
Enasidenib: The Importance of Context

Jessica K. Altman, MD
Northwestern Univ.
Chicago, IL
Clinical Considerations for the Use of GO and Enasidenib

Richard Pazdur, MD
U.S. Food and Drug Administration
Silver Spring, MD
Panel Discussion

back to top

Blood and Beyond: The Art of Perception

Sunday, December 10, 2017, 4:30 p.m. - 6:00 p.m.
Georgia World Congress Center, Bldg A- Lvl 4- Marcus Aud.

Scientifically and clinically, the study of blood commands a professional engagement that can lead hematologists to lose sight of the complex notions held by the non-medical world. This session will showcase art historian Amy E. Herman, whose work shines a unique light on the intersection of medicine and humanity. In her celebrated seminar, The Art of Perception, Ms. Herman has trained experts from many fields how to perceive and communicate better. By showing people how to look closely at images, she helps them hone their visual intelligence, a set of skills all individuals possess but that few know how to use effectively. Ms. Herman has spent more than a decade teaching doctors to observe patients instead of their charts, helping police officers separate facts from opinions when investigating a crime, and training professionals from the Federal Bureau of Investigation, the State Department, Fortune 500 companies, and the military to recognize the most pertinent and useful information. Her lessons highlight far more than the physical objects you may be missing; they teach you how to recognize visual clues. Ms. developed and conducts all sessions of The Art of Perception using the analysis of works of art to improve perception and communication.

Chair:

Bob Löwenberg, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Speaker:

Amy E. Herman, JD, MA
Author, Visual Intelligence
New York, NY
The Art of Perception

back to top

Consultative Hematology Course

Monday, December 11, 2017, 7:00 a.m. - 11:30 a.m.
Omni Hotel at CNN Center, Int'l Blrm. A-D No. Twr. M2

The ASH Consultative Hematology Course is an interactive half-day program led by faculty familiar with consultative practice issues and commonly-encountered clinical problems that require the expertise of a hematologist. Participants in this program will engage in interactive case-based presentations and discussions focusing on non-malignant hematology topics such as thrombosis, anemia, and sickle cell disease. Update your core knowledge of non-malignant hematology by attending this course!

Co-Chairs:

Michael Linenberger, MD
Fred Hutchinson Cancer Research Center, University of Washington
Seattle, WA

Paula D. James, MD
Queen's University
Kingston, ON, Canada

Speakers:

Maureen Okam Achebe, MD, MPH
Hematology Division Brigham and Women's
Boston, MA
Anemias in Pregnancy

Julie Kanter, MD
Medical University of South Carolina
Charleston, SC
Sickle Cell Disease in Adults: What does the consultant hematologist need to know?

Michael Linenberger, MD
Fred Hutchinson Cancer Research Center, University of Washington
Seattle, WA
Hematologic Manifestations of Rheumatologic Disease & Vice Versa

Maureen Okam Achebe, MD, MPH
Hematology Division Brigham and Women's
Boston, MA
Panel Discussion I

Paula D. James, MD
Queen's University
Kingston, ON, Canada
Uncommon Coagulopathies

Jason R. Gotlib, MD
Stanford University School of Medicine
Stanford, CA
Eosinophilia & Mastocytosis: The Other White Cells

Stephan Moll, MD
University of North Carolina
Chapel Hill, NC
Thrombosis in Unusual Places

Jason Gotlib, MD
Stanford Cancer Center
Stanford, CA
Panel Discussion II

back to top

Featured Topic Discussion: Combination Therapies: How Are We Deciding What to Utilize?

Combination Regimens with Immunotherapies

Monday, December 11, 2017, 12:15 p.m. - 1:15 p.m.
Georgia World Congress Center, Bldg B- Lvl 5- Murphy BR 1-2

This session will highlight research that was submitted as abstracts and presented predominantly as posters at the annual meeting. In this session, a pair of experts will summarize the abstracts and comment on their relevance to an emerging and timely research area.

Speakers:

Steven Grant, MD
Virginia Commonwealth University
Richmond, VA

Donna Przepiorka, MD,PhD
Food & Drug Administration
Silver Spring, MD

back to top

Featured Topic Discussion: Hemophilia Revolution

Sunday, December 10, 2017, 11:15 a.m. - 12:15 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B405-B407

This session will highlight research that was submitted as abstracts and presented predominantly as posters at the annual meeting. In this session, a pair of experts will summarize the abstracts and comment on their relevance to an emerging and timely research area.

Speakers:

Barbara A Konkle, MD
Bloodworks Northwest
Seattle, WA

David Lillicrap, MD
Queen's University Richardson Laboratory
Kingston, ON, Canada

back to top

Global Hematology Symposium

Multifaceted Strategy to Treat Sickle Cell Disease in Ghanaian Children

Monday, December 11, 2017, 12:15 p.m. - 1:15 p.m.
Georgia World Congress Center, Bldg A- Lvl 4- Marcus Aud.

Dr. Ohene-Frempong will speak about his work with public and private sectors in Ghana to build comprehensive screening and early intervention processes for children with sickle cell disease and review the outcomes for children who have been enrolled in these programs. Dr. Leslie Kean, the session chair, will also provide a brief address about volunteer opportunities through the ASH partnership with Health Volunteers Overseas.

Chair:

Leslie Kean, MD, PhD
Seattle Children's Research Institute
Seattle, WA

Speaker:

Kwaku Ohene-Frempong, MD
Sickle Cell Foundation of Ghana
Elkins Park, PA
Multifaceted Strategy to Treat Sickle Cell Disease in Ghanaian Children

back to top

Hematology Course Directors’ Workshop

Pedagogy, New Techniques, Scholarship, and ASH MEI Spotlight

Sunday, December 10, 2017, 7:00 a.m. - 9:00 a.m.
Omni Hotel at CNN Center, Grand Blrm A- No. Twr- M4

The Hematology Course Directors’ Workshop will continue to offer practical tips and a place of camaraderie for those involved with teaching hematology to medical students. The workshop will focus on pedagogy, new techniques, scholarship on a yearly basis, and a highlight of one participant’s project from the 2016 ASH Medical Educators Institute. Topics to be covered include Knowles’ adult learning theory, a pro and con discussion on the flipped classroom, and an examination of qualitative research methodology.

Chair:

Leslie Renee Ellis, MD
Wake Forest School of Medicine
Winston-Salem, NC

Speakers:

Jennifer C. Kesselheim, MD, MEd
Dana-Farber Cancer Institute
Boston, MA
Knowles’ Adult Learning Theory

Rajiv K. Pruthi, MBBS
Mayo Clinic
Rochester, MN
The Flipped Classroom: Pros

Leslie Renee Ellis, MD
Comprehensive Cancer Center of Wake Forest Baptist Health
Winston-Salem, NC
The Flipped Classroom: Cons

Amy Sullivan, EdD
Harvard Medical School
Boston, MA
An Overview of Qualitative Research Methodology

Ariela L. Marshall, MD
Mayo Clinic
Rochester, MN
ASH Medical Educators Institute Spotlight

back to top

How to Get Published in a Peer-Reviewed Journal

Saturday, December 9, 2017, 11:15 a.m. - 12:15 p.m.
Georgia World Congress Center, Bldg B- Lvl 2- B213-B214

The ability to communicate one's work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. This talk will provide insight into the elements of a high-quality manuscript worthy of publication in Blood and tips on avoiding common errors that might result in rejection.

Chair:

Bob Löwenberg, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

back to top

Meet the Blood Editors

What Makes a Great Paper for Blood?

Sunday, December 10, 2017, 11:15 a.m. - 12:15 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B408

These sessions provide the opportunity for attendees to meet with the associate editors of Blood and discuss recent changes to the journal as well as submission and peer-review processes and policies, with each session giving a unique focus. Seating is limited and available on a first-come, first-served basis. back to top

Meet the Blood Editors

What Makes a Great Paper for Blood?

Monday, December 11, 2017, 12:15 p.m. - 1:15 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B408

These sessions provide the opportunity for attendees to meet with the associate editors of Blood and discuss recent changes to the journal as well as submission and peer-review processes and policies, with each session giving a unique focus. Seating is limited and available on a first-come, first-served basis. back to top

Networking Reception for Female Hematologists

Monday, December 11, 2017, 7:30 p.m. - 9:00 p.m.
Omni Hotel at CNN Center, Int'l Blrm. E-F No. Twr. M2

This workshop and networking reception will provide an opportunity for female hematologists to gather in an informal environment. The goal of the event is to facilitate an exchange between senior and more junior hematologists in an effort to cultivate mentoring. The emphasis of this year’s program underscores the importance of being proactive. In addition to remarks from the co-chairs, participants will work in small groups, led by more senior hematologists, to discuss strategies to address real-life challenges that participants will identify in advance.

RSVP online

Co-Chairs:

Christine Chomienne, MD, PhD
INSERM Hôpital Saint-Louis
Paris, France

Linda J. Burns, MD
National Marrow Donor Program/Be the Match
Minneapolis, MN

Speakers:

Linda J. Burns, MD
National Marrow Donor Program/Be the Match
Minneapolis, MN

Christine Chomienne, MD, PhD
INSERM Hôpital Saint-Louis
Paris, France

back to top

Promoting Minorities in Hematology Presentations 1

Saturday, December 9, 2017, 6:30 p.m. - 8:00 p.m.
Georgia Aquarium, Atlantic Room

Promoting Minorities in Hematology Presentations 1 and 2 will occur simultaneously.

Speakers:

Jeffrey Edwards
Stanford University School of Medicine
Stanford, CA
Targeted Inhibition of CREB for the Treatment of Pediatric Acute Myeloid Leukemia

Christina Marcelus
State University of New York Upstate Medical University
Syracuse, NY
Characterization of NTRK Fusions and Therapeutic Response to TRK inhibitors in Hematologic Malignancies

Wilton Edward Robinson Jr., MPH
Georgetown University School of Medicine
Washington, DC
Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B cell Lymphoma Patients

Cristian Taborda
Columbia University College of Physicians and Surgeons
New York, NY
Role of Microbiome Diversity in Shaping the Graft-Versus-Host Immune Response after Allogeneic Hematopoietic Stem-Cell Transplantation

Allison O. Taylor
Georgetown University School of Medicine
Washington, DC
Examination of B Cell Maturation Antigen (BCMA) and Transmembrane Activator and Caml Interactor (TACI) Expression on Plasma Cells during the Course of Multiple Myeloma

Orly Leiva, BS
Boston University School of Medicine
Boston, MA
Mechanisms of Control of Lysyl Oxidase Expression in JAK2-Mutated Myelofibrotic Cells

Elisa Quiroz, MD
Beaumont Health
Royal Oak, MI
Acute Lymphoblastic Leukemia in the Latino Population

back to top

Promoting Minorities in Hematology Presentations 2

Saturday, December 9, 2017, 6:30 p.m. - 8:00 p.m.
Georgia Aquarium, Pacific Room

Promoting Minorities in Hematology Presentations 1 and 2 will occur simultaneously.

Speakers:

Alexandra Boye-Doe
Case Western Reserve University School of Medicine
Cleveland, OH
Does RBC adhesion, as measured on a microfluidic device, change with pain in SCD?

Moses O. Evbuomwan
Oakland University William Beaumont School of Medicine
Rochester, MI
Evaluating novel VLA-4 inhibitors in combination with CXCR2 agonists as strategy to mobilize Hematopoietic Stem and Progenitor cells (HSPC)

Marjorie M. Johnson, BS
Augusta University
Augusta, 
AN908, a Novel Prodrug Conjugate of Butyrate and d-Aminolevulinate Increases ?-Globin Gene Expression in Erythroid Progenitors

Lillian Chinenye Nwanah, BA
University of Illinois
Chicago, IL
Effect of peptides blocking DREAM-PI3K binding on platelet Thrombus Formation in vivo

Christopher Miller, BS,MA
Chicago Medical School of Rosalind Franklin University of Medicine and Science
Chicago, IL
Testing If TET3 Is a Direct HIF Target during Erythropoiesis

Anjelica C Saulsberry, BS
University of Tennessee Health Science Center College of Medicine
Memphis, TN
Exploring the Relationship between Self—Management and Disease Knowledge Among Adolescents with Sickle Cell Disease

Jasmine Smith, BS
University of South Carolina School of Medicine Greenville
Greenville, SC
Hematopoietic Cell Transplant and Sickle Cell Disease: How to Maximize Use of This Curative Therapy

Maria Emma Torres
Mayo Clinic School of Medicine
Jacksonville, FL
Impact of Hospitality Houses on the Quality of Life and Mood of Hematopoietic Stem Cell Transplant Patients and Caregivers

Samuel Wilson, MD
University of Michigan Health System
Ann Arbor, 
Impact of Duffy Antigen Phenotype on Hydroxyurea Dosing Amongst Individuals with Sickle Cell Disease

back to top

Promoting Minorities in Hematology Presentations and Reception

Saturday, December 9, 2017, 6:30 p.m. - 9:00 p.m.
Georgia Aquarium, Oceans Ballroom

ASH invites all interested meeting attendees to this event which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from ASH Minority Medical Student Award and Minority Resident Hematology Award program participants. The reception will also feature poster presentations by students participating in two Minority Research Supplement programs from the National Institutes of Health (NIH) as well as an announcement about the ASH-AMFDP Award, a partnership between ASH and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Representatives from the NIH will be available to provide information about their training and research offerings. back to top

Quality Conversations on Social Media: Achieving Credibility and Efficiency Together

Sunday, December 10, 2017, 11:15 a.m. - 12:15 p.m.
Georgia World Congress Center, Bldg C- Lvl 2- C202-C204

Panelists will discuss their personal best practices for starting and maintaining quality conversations relevant to hematology on Twitter and other social media platforms. Topics to be addressed include using social media for collaboration and crowdsourcing as well as tips for more efficient use of social media.

Chair:

Joseph R. Mikhael, MD
Mayo Clinic
Scottsdale, AZ

Speakers:

Joseph R Mikhael, MD, FRCPC, MEd
Mayo Clinic
Phoenix, AZ
Introduction to Quality Conversations on Social Media

Mohamad Mohty, MD, PhD
Saint Antoine Hospital
Paris, France
Why do we need social media in medicine?

Elaine Schattner, MD
Forbes Contributor; Weill Cornell Medical College
New York, NY
Social Media Conversations: Patient’s Perspective & Security Tips

John P. Leonard, MD
Weill Cornell Medicine
New York, NY
Good tweets, bad tweets, you know I had my share

John P. Leonard, MD
New York-Presbyterian/Weill Cornell Medical Center
New York, NY
Panel Discussion

Mohamad Mohty, MD, PhD
Saint Antoine Hospital
Paris, France
Panel Discussion

Elaine Schattner, MD
Forbes Contributor; Weill Cornell Medical College
New York, NY
Panel Discussion

back to top

Special Education Session on New ASH Clinical Practice Guidelines on Venous Thromboembolism

Special Education Session on New ASH Clinical Practice Guidelines on Venous Thromboembolism (Special-Interest Sessions)

Saturday, December 9, 2017, 7:30 a.m. - 9:00 a.m.
Georgia World Congress Center, Bldg A- Lvl 4- Marcus Aud.

In response to long-standing member interest, ASH initiated an effort in 2014 to develop evidence-based clinical practice guidelines for hematology that meet the highest standards of development rigor and trustworthiness. The first ASH guidelines in development under this effort are a set of 10 guidelines on the prevention, treatment, and diagnosis of venous thromboembolism (VTE). Development of the guidelines, including systematic evidence review, is supported by the McMaster University GRADE Center.

As part of the VTE guideline development process, more than 100 thrombosis experts across 10 VTE guideline panels reviewed evidence and formulated more than 200 recommendations on VTE. In this session, the chairs of each of the 10 panels will present key recommendations from the upcoming chapters and enumerate the various Education Program sessions that will touch on these recommendations.

Co-Chairs:

Adam Cuker, MD, MS
University of Pennsylvania
Philadelphia, PA

Holger Schünemann, MD
McMaster University
Hamilton, ON, Canada

Speakers:

Adam Cuker, MD, MS
University of Pennsylvania
Philadelphia, PA
Introduction to ASH Guideline Initiatives

Holger Schünemann, MD
McMaster University
Hamilton, ON, Canada
Introduction to ASH VTE Guidelines

David Anderson, MD
Dalhousie University
Halifax, NS, Canada
Panel on Prevention of VTE in Surgical Hospitalized Patients

Mary Cushman, MD
University of Vermont
Burlington, VT
Panel on Prevention of VTE in Nonsurgical Patients

Wendy Lim, MD, MSc
McMaster University
Hamilton, ON, Canada
Panel on Diagnosis of VTE

Saskia Middeldorp, MD, PhD
Academic Medical Center
Amsterdam, Netherlands
Panel on Thrombophilia

Thomas L. Ortel, MD, PhD
Duke University Medical Center
Durham, NC
Panel on Treatment of VTE

Daniel M. Witt, PharmD
University of Utah College of Pharmacy
Salt Lake City, UT
Panel on Optimal Management of Anticoagulation Therapy

Gary H. Lyman, MD, MPH, FRCP
Fred Hutchinson Cancer Research Center
Seattle, WA
Panel on Prevention and Treatment of VTE in Patients With Cancer

Shannon Marie Bates, MD
McMaster University
Hamilton, Canada
Panel on VTE in the Context of Pregnancy

Sarah O'Brien, MD, MSc
Nationwide Children's Hospital
Columbus, OH
Panel on VTE in Pediatric Populations

Adam Cuker, MD, MS
University of Pennsylvania
Philadelphia, PA
Panel on Heparin-Induced Thrombocytopenia

back to top

Special Session on CAR T Therapy

Saturday, December 9, 2017, 4:00 p.m. - 5:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 1- Hall C1

With the U.S. Food and Drug Administration’s (FDA) recent approval of CAR-T cell therapy, interest in this technology is exponentially growing. For example, why do we need standards for the provision for immune effector cell therapy and what should those standards be? We know about the short term toxicities of this therapy, but what are longer-term complications of CAR-T cell therapy, and what should the referring hematologist know about these patients when they return home? And what do we know about the financial toxicity of offering these therapies to health systems?

There are at least 130 abstracts investigating CAR-T cell therapy at the 2017 ASH Annual Meeting. This special session looks at the modality from a slightly different aspect than the typical presentations at this meeting and will allow the speakers and audience to have a dialogue about issues regarding this exciting and promising therapy.

Chair:

Samuel M. Silver, MD, PhD
University of Michigan
Ann Arbor, MI

Speakers:

Elizabeth J. Shpall, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
The FACTS of CARTOX: What are the Standards for Institutions Offering Immune Effector Cells?

Shannon L Maude, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, PA
Monitoring for Long-Term Complications of CAR T Therapies

Samuel M. Silver, MD, PhD
University of Michigan
Ann Arbor, MI
The Health Systems and Financial Implications of Offering CAR T Therapies

back to top

Special Session on Systems-Based Hematology

Sunday, December 10, 2017, 4:30 p.m. - 6:30 p.m.
Georgia World Congress Center, Bldg B- Lvl 4- B401-B402

The systems-based hematologist is a unique career opportunity for hematologists in both university and community-practice. Employed in part or full by a hospital or health care system, this hematologist optimizes individual patient care for patients with blood diseases. This hematologist also ensures that patients with blood disorders or requiring blood-derived products throughout the health system receive high-quality care that is evidence-based and consistent with nationally accepted guidelines.

This second yearly session on systems-based hematology is an opportunity for education and networking among those in or interested in practice in systems-based hematology. Speakers will highlight examples of key roles and skills for systems-based hematologists in a number of health care systems, after which a representative of this community will solicit input on the educational needs of this community. The sessions will followed by a speed networking event.

Chair:

Nathan T. Connell, MD,MPH
Brigham and Women's Hospital
Boston, MA

Speakers:

Ravindra Sarode, MD
UT Southwestern Medical Center
Dallas, TX
Lessons Learned from a Choosing Wisely® Champion

Colleen Morton, MD
Vanderbilt University Medical Center
Nashville, TN
From One System to Another: Systems-Based Hematology Success in the Academic and Community Settings

Nathan T. Connell, MD,MPH
Brigham and Women's Hospital
Boston, MA
The Future of Systems-Based Hematology Education at the ASH Annual Meeting

back to top

Special Session on the Hematologic Response to Mass Casualty Radiological Disasters

Sunday, December 10, 2017, 9:30 a.m. - 11:00 a.m.
Georgia World Congress Center, Bldg B- Lvl 4- B401-B402

This session is a discussion of existing preparations for mass casualty radiological disasters that affect the United States and how the hematology and oncology community will be brought to bear to assist. The session will begin with a description of the disaster scenario, its complications and the resulting surge in medical care that will impact the entire Nation (this can be applied to any nation in the world, and an international radiological connection will be included). The scenario will be followed by a brief overview of the Radiation Injury Treatment Network (RITN) including the preparedness efforts to date as well as description of resulting resources available to the Hem/Onc community. The response to the 2011 Tohoku Earthquake that resulted in the tsunami and the Fukushima Nuclear Power Plant disaster will be reviewed, including the response complications for a hospital and community that had to make do with scarce resources for an extended period of time. Finally, the session will be capped with the perspective of a bone marrow transplant (BMT) physician who has been involved with the implementation of preparedness for an RITN Center, and the successes, failures and lessons learned from the experience. The session will culminate with recommendations for those who are not engaged with preparedness efforts at their institution to improve the preparedness of their institution and Hem/Onc divisions.

Chair:

Dennis L Confer, MD
National Marrow Donor Program
Minneapolis, MN

Speakers:

Cullen Case Jr.
National Marrow Donor Program
Minneapolis, MN
Scenario Description and Radiation Injury Treatment Network (RITN) Overview

Kenneth E Nollet, MD, PhD
Fukushima Medical University
Fukushima, JPN
Hematology in Hell and High Water: Lessons from Japan's Earthquake, Tsunami, and Nuclear Crisis

Nelson J. Chao, MD
Duke University Medical Center
Durham, 
Bone Marrow Transplantation Perspective from a RITN Physician

back to top

Special Symposium on Quality

Effective Implementation of Evidence-Based Pathways and Clinical Guidelines

Saturday, December 9, 2017, 2:00 p.m. - 3:30 p.m.
Georgia World Congress Center, Bldg C- Lvl 2- C202-C204

Adhering to evidence-based clinical guidelines is recognized by both medical practitioners and administrators as a key pathway to improving quality of care, whether in complex, distributed health care systems or in community-based practices. Yet despite the demonstrated advantages that guidelines provide in the context of care delivery, implementing recommendations is fraught with potential pitfalls. Culture, cost, and complexity are chief among a variety of barriers to successful implementation of evidence-based pathways and clinical guidelines. Notwithstanding these challenges, real-world examples have established that implementation is achievable across a variety of clinical settings. These issues are especially important in hematology, as both malignant and non-malignant hematologic disorders are uncommon and complex.

This session will explore issues related to the implementation of evidence-based pathways and clinical guidelines, examine research supporting effective strategies for developing implementation methodologies, and review practical examples of successful implementation of pathways or guidelines in large-scale clinical settings.  The session will include practical takeaways for immediate use by practitioners and administrators alike.

Co-Chairs:

Colleen Morton, MD
Vanderbilt University Medical Center
Nashville, TN

William A. Wood, MD, MPH
The University of North Carolina at Chapel Hill
Chapel Hill, NC

Speakers:

Anna Gagliardi, PhD
University of Toronto
Toronto, Canada
Implementation Science Research for Effective Guideline Implementation

Craig Robbins, MD, MPH
Kaiser Permanente Care Management Institute
Oakland, CA
Health Care Quality: Overcoming Barriers to Evidence-Based Care

Derek Raghavan, MD, PhD
Levine Cancer Institute
Charlotte, NC
Implementation Is Practical: Examples of Successful, Large-Scale Guideline Implementations

back to top

Training Program Directors’ Workshop

Friday, December 8, 2017, 12:00 p.m. - 5:00 p.m.
Omni Hotel at CNN Center, Int'l Blrm. D No. Twr. M2

The Training Program Directors’ Workshop provides an interactive forum for directors of all hematology-related training programs to learn from educators, regulators, and each other. This year’s session will feature a new format. Three topics will be covered, and two of them will have table-top exercises to engage participants.

Dr. Christian Cable will return for an update from the Accreditation Council for Graduate Medical Education (ACGME). Dr. Cable is the current chair of the ACGME’s Residency Review Committee for Internal Medicine and a former hematology/oncology training program director.

Drs. Alice Cohen and Gerald Soff will discuss how to have an effective career development talk with fellows, with a focus on counseling fellows for careers in hematology. Topics to be covered will include whether to double board and lab-based science versus clinical research.

Drs. Alfred Lee and Michael Borowitz will share innovative tools they have employed in hematology training. The session will provide a chance to refocus on the basics of a hematology fellowship: teaching hematology to fellows.

Chair:

Ann S. LaCasce, MD, MSc
Dana-Farber Cancer Institute
Boston, MA

Speakers:

Christian Cable, MD
Baylor Scott & White Health
Round Rock, TX
ACGME Update 2017

Alice J. Cohen, MD
Newark Beth Israel Medical Center
Newark, NJ
Having “The Talk” With Fellows

Gerald A. Soff, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Having “The Talk” With Fellows

Michael Borowitz, MD, PhD
Johns Hopkins Medical Institute
Baltimore, MD
It’s in Our Blood

Alfred Lee, MD, PhD
Yale University School of Medicine
New Haven, CT
It’s in Our Blood

back to top